The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Defining Administration Complexity by the Drug, Not the Diagnosis

Defining Administration Complexity by the Drug, Not the Diagnosis

January 10, 2022 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR is working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologics. Those codes take into account the complexity of these drugs and the additional time needed for their delivery.

You Might Also Like
  • The Most Cost-Effective Diagnosis Is the Correct Diagnosis
  • Coding Corner Answers: A Drug Administration Quiz
  • Coding Corner Questions: A Drug Administration Quiz
Also By This Author
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
headshot of Marcus Snow

Dr. Snow

“If there is not appropriate reimbursement for the administration of biologic drugs, practices may not be able to continue offering these critical therapies in office,” says Marcus Snow, MD, chair of the ACR Committee on Rheumatologic Care (CORC).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Currently, a number of Medicare contractors (MACs) do not recognize certain biologic drugs as reimbursable under complex administration codes. Instead, they require rheumatology practices to code administration of these drugs under simple/therapeutic codes.

Such policies fail to recognize that biologics, regardless of the disease they are used to treat, are inherently complex and therefore should be reimbursed at the higher rate under the complex administration codes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

An ACR position statement, presented by CORC and sent to key stakeholders in 2019, details the reasons biologics should be reimbursed under complex administration codes, regardless of the specialty using them.

Complexity Determined by the Drug, Not the Diagnosis

According to both Current Procedural Terminology (CPT) and Centers for Medicare & Medicaid Services (CMS) manuals, biologics meet the definitions for chemotherapy services and are reimbursed under complex chemotherapy codes (CPT 96401–96413). As detailed in the ACR’s position statement, the higher reimbursement based on these complex codes takes into account the comprehensive work required to approve, administer and monitor biologics, usually requiring direct physician supervision.

Administration of biologics in rheumatology and other specialties entails the same level of expertise as in oncology to ensure proper and safe use. “The determination of whether it is appropriate to use the complex chemotherapy administration codes is based on the complexity of the drug, not the patient’s diagnosis,” says Dr. Snow.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR’s statement lists the following key positions on biologics:

  • Use of biologics should be supervised and carried out by specially trained practitioners with knowledge, training, and experience to properly handle, administer, and monitor biological agents;
  • All providers and payers should follow consistent policies for documentation of medical necessity, complex administration protocols, and proper coding and reimbursement for the infusion and injection of biologics;
  • All biological agents should be considered highly complex for administration, monitoring, coding, and reimbursement purposes and be covered at an appropriate level by health plans;
  • Unique CPT codes are warranted for biologics with separate formulations (such as those administered subcutaneous versus intravenous) given their distinct indications, risks and target populations; and
  • Policies on where biologics are administered should promote the highest standards of safety and allow patients to receive treatments in facilities with specialty trained practitioners overseeing their infusion.

To date, however, certain MACs have set policy on coding and reimbursement of biologics in rheumatology by issuing Local Coverage Articles (LCAs) that require rheumatology practices to use the simple/therapeutic code (CPT 96365) for administering biologics, in effect barring the use of complex coding for these drugs. This move by the MACs appears to define complexity more by a patient’s diagnosis (e.g., cancer) than by the complexity of the drug itself.

Pages: 1 2 3 | Single Page

Filed Under: Billing/Coding, Biologics & Biosimilars, Legislation & Advocacy Tagged With: Biologics, Coding, Committee on Rheumatologic Care (CORC), Local Coverage Article (LCA), Local Coverage Determination (LCD), Medicare Administrative Contractors (MACs)

You Might Also Like:
  • The Most Cost-Effective Diagnosis Is the Correct Diagnosis
  • Coding Corner Answers: A Drug Administration Quiz
  • Coding Corner Questions: A Drug Administration Quiz
  • ACR-Led Resolutions at AMA House of Delegates Meeting Protect Rheumatology Practices, Patient Access

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)